What is hydroquinone usp 4

what is hydroquinone usp 4

Hydroquinone Cream

Mar 01,  · HYDROQUINONE USP, 4% SKIN BLEACHING CREAM is indicated for the gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation. HYDROQUINONE USP, 4% SKIN BLEACHING CREAM is indicated for the gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation.

For further information about unapproved drugs, click here. Chemically, hydroquinone is C 6 H 6 O 2 and has a molecular weight of Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3,4-dihydroxyphenylalanine dopa Denton, C. Exposure to sunlight or ultraviolet light will cause repigmentation of bleached areas Parrish, J.

Prior history of sensitivity or allergic reaction to hydroquinone or to any of the ingredients of the product. The safety of topical hydroquinone use during pregnancy or for children 12 years and under has not been established. Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.

Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people. Since this product contains no sunscreen, an effective broad spectrum sun blocking agent should be used and unnecessary solar exposure avoided, or protective clothing should be worn to cover bleached skin in order to prevent repigmentation from occurring.

Hydroquinone may produce exogenous ochronosis, a gradual blue-black darkening how to fix a broken bra wire the skin. If this condition occurs, discontinue treatment and consult your physician. The majority of patients developing this condition are Black, but it may also occur in Caucasians and Hispanics.

Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin; check within 24 hours. Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response further treatment is not advised. Close patient supervision is recommended. Hydroquinone is a skin bleaching agent which may produce unwanted cosmetic effects if not used as directed.

The physician should be familiar with the contents of this insert before prescribing or dispensing this medication. Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight sustains melanocytic activity. To prevent repigmentation, during treatment and maintenance therapy, sun exposure on treated skin should be avoided by application of a how to move a trailer spectrum sunscreen SPF 15 or greater or by use of protective clothing.

Keep this and all medications out of reach of children. In case of accidental ingestion, call a physician or a poison control center immediately. Patients are cautioned on concomitant use of medications that are known to be photosensitizing.

Studies of hydroquinone in animals have demonstrated some evidence of carcinogenicity. The carcinogenic potential of hydroquinone in humans is unknown. Published studies have demonstrated that hydroquinone is a mutagen and a clastogen. Treatment with hydroquinone has resulted in positive findings for genetic toxicity in the Ames assay in bacterial strains sensitive to oxidizing mutagens, in in vitro studies in mammalian cells, and in the in vivo mouse micronucleus assay.

Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether topical hydroquinone can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Topical hydroquinone should be given to a pregnant woman only if clearly needed. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when topical hydroquinone is administered to a nursing woman.

Safety and effectiveness for pediatric patients below the age of 12 years have not been established. The following adverse reactions have been reported: dryness and fissuring of paranasal and infraorbital areas, erythema, and stinging.

Occasional hypersensitivity localized contact dermatitis may develop. If this occurs, the medication should be discontinued and the physician notified immediately. There have been no systemic reactions reported from the use of topical hydroquinone.

However, treatment should be limited to relatively small areas of the body at one time, since some patients experience a transient skin reddening and a mild burning sensation which does not preclude treatment.

If no improvement is seen after 2 months of treatment, use of this product should be discontinued. There is no what is a hybrid class dosage for pediatric patients under 12 years of age except under the advice and supervision of a physician. The chemical name is 1,4 dihydroxybenzene, and the structural formula of hydroquinone is:. WARNINGS Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people.

Information for Patients - Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight sustains melanocytic activity.

Avoid contact with eyes and mucous membranes. Drug Interactions - Patients are cautioned on concomitant use of medications that are known to be photosensitizing.

Carcinogenesis, Mutagenesis, Impairment of How long should potatoes boil - Studies of hydroquinone in animals have demonstrated some evidence of carcinogenicity. Pregnancy: Teratogenic Effects: Pregnancy Category C - Animal reproduction studies have not been conducted with topical hydroquinone.

Nursing Mothers - It is not known whether this drug is excreted in human milk. Pediatric Use - Safety and effectiveness for pediatric patients below the age of 12 years have not been established. Relabeled By: Preferred Pharmaceuticals Inc. Product Information. Inactive Ingredients. Product Characteristics.

Marketing Information. Labeler - Preferred Pharmaceuticals, Inc. Registrant - Preferred Pharmaceuticals, Inc.

Information for Patients

Hydroquinone USP, 4% Time Release Cream is indicated for the gradual treatment of ultraviolet induced dyschromia and discoloration (such as chloasma, melasma, freckles, and senile lentigines) resulting from the use of oral contraceptives, pregnancy, hormone replacement therapy, or skin trauma. HYDROQUINONE 4% CREAM: Skin Bleaching Cream Rx Only. FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE NDC: DESCRIPTION: Each gram of HYDROQUINONE USP, 4% SKIN BLEACHING CREAM contains 40 mg hydroquinone, in a cream base of Glyceryl Monostearate, Mineral Oil, PEG Propylene Glycol Stearate, Polyoxl Stearate, Propylene Glycol, . HYDRO-Q ® contains hydroquinone USP 4%. Hydroquinone is 1, 4-Benzenediol {CAS }. Hydroquinone is structurally related to monobenzone. Hydroquinone occurs as fine white needles. The drug is freely soluble in water and in alcohol and has a pKa of Chemically, hydroquinone is designated as p-dihydroxybenzene; the empirical formula is C6H6O2; The molecular weight is

Medically reviewed by Drugs. Last updated on March 1, For further information about unapproved drugs, click here. Chemically, hydroquinone is C 6 H 6 O 2 and has a molecular weight of The chemical name is 1,4 dihydroxybenzene, and the structural formula of hydroquinone is:.

Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3,4-dihydroxyphenylalanine dopa Denton, C.

Exposure to sunlight or ultraviolet light will cause repigmentation of bleached areas Parrish, J. Prior history of sensitivity or allergic reaction to hydroquinone or to any of the ingredients of the product. The safety of topical hydroquinone use during pregnancy or for children 12 years and under has not been established. Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people.

The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people. Since this product contains no sunscreen, an effective broad spectrum sun blocking agent should be used and unnecessary solar exposure avoided, or protective clothing should be worn to cover bleached skin in order to prevent repigmentation from occurring.

Hydroquinone may produce exogenous ochronosis, a gradual blue-black darkening of the skin. If this condition occurs, discontinue treatment and consult your physician. The majority of patients developing this condition are Black, but it may also occur in Caucasians and Hispanics. Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin; check within 24 hours.

Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response further treatment is not advised. Close patient supervision is recommended. Hydroquinone is a skin bleaching agent which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this medication.

Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight sustains melanocytic activity. To prevent repigmentation, during treatment and maintenance therapy, sun exposure on treated skin should be avoided by application of a broad spectrum sunscreen SPF 15 or greater or by use of protective clothing. Avoid contact with eyes and mucous membranes.

Keep this and all medications out of reach of children. In case of accidental ingestion, call a physician or a poison control center immediately.

Patients are cautioned on concomitant use of medications that are known to be photosensitizing. Studies of hydroquinone in animals have demonstrated some evidence of carcinogenicity. The carcinogenic potential of hydroquinone in humans is unknown. Published studies have demonstrated that hydroquinone is a mutagen and a clastogen.

Treatment with hydroquinone has resulted in positive findings for genetic toxicity in the Ames assay in bacterial strains sensitive to oxidizing mutagens, in in vitro studies in mammalian cells, and in the in vivo mouse micronucleus assay. Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether topical hydroquinone can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

Topical hydroquinone should be given to a pregnant woman only if clearly needed. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when topical hydroquinone is administered to a nursing woman.

Safety and effectiveness for pediatric patients below the age of 12 years have not been established. The following adverse reactions have been reported: dryness and fissuring of paranasal and infraorbital areas, erythema, and stinging. Occasional hypersensitivity localized contact dermatitis may develop. If this occurs, the medication should be discontinued and the physician notified immediately. There have been no systemic reactions reported from the use of topical hydroquinone. However, treatment should be limited to relatively small areas of the body at one time, since some patients experience a transient skin reddening and a mild burning sensation which does not preclude treatment.

If no improvement is seen after 2 months of treatment, use of this product should be discontinued. There is no recommended dosage for pediatric patients under 12 years of age except under the advice and supervision of a physician.

No representation is made as to generic status or bioequivalency. Labeler - Marlex Pharmaceuticals, Inc. Drug Class. Topical depigmenting agents. Related Drugs. Subscribe to our newsletters. FDA Safety Alerts for all medications. Daily MedNews. Monthly Newsletter. I accept the Terms and Privacy Policy. Email address.

Select one or more newsletters to continue. Product Information. Inactive Ingredients. Marketing Information.



Plus d'articles dans cette categorie:
<- How to use a transit to shoot grade - What does the name alva mean->

0 reflexions sur “What is hydroquinone usp 4

Ajouter un commentaire

Votre courriel ne sera pas publie. Les champs requis sont indiques *